Sanofi India Limited has informed the Exchange regarding appointment of Mr. Mahadev Gawade as the Site Director Goa, w.e.f. August 11, 2025.
SANOFI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sanofi India reported Q1 FY26 revenue from operations of ₹4,063 million, down about 12% from ₹4,635 million in Q1 FY25, while profit after tax from continuing operations rose to ₹695 million (EPS ₹30.18) from ₹682 million a year ago. Half-year revenue stood at ₹9,422 million with PAT of ₹1,890 million. The Board approved the unaudited financial results for the quarter and half-year ended June 30, 2025. Separately, Ms. Renee Amonkar will retire as Whole-time Director and Site Director – Goa on August 11, 2025, and will cease to be a KMP and Senior Management Personnel. Mr. Mahadev Gawade, previously with Sandoz India, has been appointed as Additional and Whole-time Director for three years and as Site Director – Goa, effective August 11, 2025, subject to shareholder approval. A subsequent event note also mentions a promotion and distribution agreement with Emcure Pharmaceuticals for the Oral Anti-diabetic (OAD) portfolio.
Q1 revenue declined year-on-year, but profitability and EPS improved, suggesting better cost management. The director change is a planned succession and unlikely to affect operations; the new Emcure partnership for OAD products could support future revenue from that segment.